SCHEMBL3907933

SCHEMBL3907933

O=S(=O)(Nc1ccccc1)c1ccc2c(c1)CCCC2CNC1=NCCN1

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 12/20 0.54
KDM4C Q9H3R0 7/20 0.47
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902313 0.91 HTR6 (0.52) HTR6KDM4C
SCHEMBL315964 0.88 HTR6 (0.70) HTR6KDM4C
SCHEMBL3904070 0.86 HTR6 (0.51) HTR6KDM4C
SCHEMBL12428546 0.78 HTR1A (0.53) KDM4C
SCHEMBL3902324 0.78 HTR6 (0.57) HTR6
SCHEMBL3900323 0.77 HTR6 (0.49) HTR6KDM4C
SCHEMBL3912579 0.76 HTR6 (0.62) HTR6
SCHEMBL3904064 0.74 HTR6 (0.58) HTR6HTR2CHTR2B
SCHEMBL3904061 0.74 HTR6 (0.58) HTR6HTR2CHTR2B
SCHEMBL3952171 0.73 HTR6 (0.74) HTR6HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076489-A1 ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF F. Hoffmann-Roche AG (CH) 2009-07-08 EP disclosed
US-7531577-B2 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-05-12 US disclosed
US-20080015208-A1 Arylsulfonamidyl tetralin derivatives and uses thereof ROCHE PALO ALTO LLC 2008-01-17 US disclosed
WO-2007147762-A1 ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015208-A1 Arylsulfonamidyl tetralin derivatives and uses thereof HTR6, TPH1, HTR1B HTR6 1/4885KDM4C 4108/4885HTR2C 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.